ClinicalTrials.gg
RecruitingNCT06886165MAPUpdated Sep 18, 2026

My Avenue to helP - Adaptive Mentalization-based Integrative Treatment Compared to Management as Usual for Youths With Multiple Problems: a Non-Randomized Controlled Feasibility Trial

An interventional study of My Avenue to HelP and Management as Usual in Mental Health Care, AMBIT and Adaptive Mentalization-Based Integrative Treatment, sponsored by Pia Jeppesen. Recruiting at 1 site in Denmark. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by Pia Jeppesen · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
12 Years to 17 Years
Sex
All
01

Study summary

My Avenue to HelP (MAP) is a non-randomized feasibility study testing the implementation of a cross-sectoral collaboration targeted youths, aged 12-17 years, with multiple social and psychological problems. MAP is a one-year intervention based on Adaptive Mentalization-Based Integrative Treatment (AMBIT). MAP is not a new treatment method, but rather a new way of offering and organizing support in the existing network around the young person. The objective is to create a new way for professionals across sectors to collaborate in supporting our most vulnerable youth. Thereby, the investigators aim to benefit the youths by incorporating a mentalizing stance to promote lasting changes beyond the intervention period. The MAP Project will run from 2025 to 2027.

The research will consist of two work packages (WPs)

  • WP1 will test the feasibility of the MAP project examining a) whether young people can be successfully recruited to the project b) if the evaluation design and methods are feasible and c) if the intervention is feasible to participants and employees (quantitatively).
  • WP2 will assess implementation determinants and evaluate the implementation strategies employed in the project. Furthermore, the acceptability of the intervention will qualitatively be assessed by interviews with selected participants, their parents, as well as employees.

Participants:

In total 60 youths aged 12-17 years from Region Zealand, Denmark:

  • 40 youths will be enrolled and receive the one-year MAP Intervention; 30 youths residing in Roskilde Municipality and 10 residing in Lejre Municipality
  • 20 youths from other municipalities in Region Zealand will be included in the trial as a control group.

To assess the nature and extent of the mental health problems and potential psychiatric disorders among the participating youths, the parents and the young person will be asked to complete an online questionnaire (Development and Well-Being Assessment (DAWBA)).

02

Conditions studied

  • Mental Health Care
  • AMBIT
  • Adaptive Mentalization-Based Integrative Treatment
  • Child and Adolescent Psychiatry
  • Health Care Professionals
  • Mental Health Services
  • Community Mental Health Services
  • Emergency Services, Psychiatric
  • Social Work, Psychiatric

Browse trials for

Keywords

  • AMBIT
  • Adative Mentalization-Based Integrative Treatment
  • Child and Adolescent Psychiatry
  • Cross-sectoral Collaboration
  • Interdisiplinary Collaboration
  • Implementation
  • Municipalities
  • Mentalization
  • Social Functioning
  • CAMHS
  • Feasibility Study
  • Primary Health Care
  • Child and Adolescent Mental Health Services
03

In context

Social Adjustment

88 studies on the registry are indexed under Social Adjustment; 21 are open to participants now.

This study's planned enrollment of 60 is below the median of 73 across 68 interventional studies indexed under Social Adjustment.

Browse Social Adjustment studies →

Lead sponsor

This is the only study on the registry with Pia Jeppesen as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Criterium A) Documented record of multiple problems defined as at least 2 of the following: (i) Absence from school / non-adherence to education (ii) Risk behaviors like alcohol or cannabis abuse, or repeated suicide attempts or self-harm requiring somatic treatment.(iii) Repeated visits at emergency-, trauma-, or acute wards. And/or one of the following: (iv) Contact with police or legal justice system. (v) Homelessness within the last year.
  • Criterium B) Age 12-17 years at time of inclusion.
  • Criterium C) Strong indication of mental disorders defined as a diagnosis of a mental disorder. The type of mental disorders will be further substantiated using the DAWBA after recruitment (Goodman et al., 2000).
  • Criterium D) Written/signed from all legal guardians (in most cases both parents) and oral consent from youths aged 15 years and older. Written/signed informed consent from the youths themselves will be collected when they turn 18 if they do so during the study period.

Exclusion criteria

Exclusion Criteria:

  • Indications of substantial intellectual disability corresponding to IQ below 50, or a level of daily and social functions that do not enable participation in research (e.g., if the young person is not deemed to have the capacity to understand the implications of the study and provide oral consent).
  • Not living in Region Zealand.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    MAP intervention

    Participants in the experimental arm of the MAP-Project will receive one year of treatment with the MAP-intervention.

    Behavioral: My Avenue to HelP

  • Active comparator
    Management as Usual, MAU

    Management as Usual will be carried out in the diverse municipalities of residence of the control and the Child and Adolescent Mental Health Services in Region Zealand.

    Behavioral: Management as Usual

Interventions

  • BehavioralMy Avenue to HelP

    The MAP intervention is based on AMBIT principles. A MAP team, consisting of designated employees from CAMHS and two municipalities, will be trained in AMBIT. A Key-Worker and a Mentalizing Case Manager will be assigned to each participant and step into the existing network, taking responsibility for integrating AMBIT principles into all aspects of the work with and around the young person. The Key-worker from the MAP team is responsible for reaching out to the young person at least once a week during the intervention. The Mentalizing Case Manager ensures that mentalization is upheld in the professional network. CAMHS will offer treatment as usual in accordance with the existing evidence-based clinical guidelines and best practice for any specific mental health disorder. The MAP team members will meet once a week to work as a team and collaborate closely with family members and other potential informal caregivers. The network of helpers will meet and coordinate monthly.

  • BehavioralManagement as Usual

    Participants in the control group will receive non-manualized, standard treatment in CAMHS in collaboration with their municipality of residence, following local practice and guidelines. The MAU will be slightly enhanced compared to standard treatment: a) the young people will have an open case file during one year of participation in the MAP project (and longer if indicated), and b) the standard care services will receive feedback from the research assessment at baseline (after approval of the specific content from parents and the young person) in order to help the young person's caseworker to coordinate the support. These enhancements are made to improve the cohesion of care for the young person, yet without applying the mentalization-based AMBIT principles and MAP teams of the MAP treatment condition. principles applied in the MAP treatment condition.

06

What researchers measure

Primary outcomes

  1. Feasibility Outcome 1: Recruitment

    Feasibility outcome 1 will be assessed by calculating the proportion of families that accept inclusion out of those who fulfill inclusion criteria. The intervention will be deemed acceptable if ≥50% of the families that are eligible (assessed at an informational meeting) also consent to participate in the MAP study.

    Time frame: 8 weeks after the last patient is enrolled

  2. Feasibility Outcome 2: Adherence to treatment protocol

    Feasibility outcome 2 will be assessed by contacting the Keyworker monthly to inquire about the contacts made/attempted by the Keyworker to the young person/network around the young person. Type of contact made between the Keyworker and the young person, and alternatively whom the Keyworker was in contact with within the indigenous network of the young person, in cases where the young person does not want direct contact with the Keyworker, will be registered as well. The intervention will be deemed acceptable if ≥70% of youths in the MAP intervention do not experience a pause of 4 continuous weeks between contacts.

    Time frame: Weekly registration of the contact between the young person and the keyworker from baseline and during the complete 52 weeks of intervention.

  3. Feasibility Outcome 3: Satisfaction with the intervention

    Feasibility outcome 3 regarding the satisfaction with treatment in MAP will be assessed using item 16.4 of the Client Satisfaction Questionnaire. The intervention will be deemed acceptable if ≥70% of youths and parents would recommend MAP to a friend.

    Time frame: Assessment within + / - 2 weeks after end of treatment

  4. Feasibility Outcome 4: Satisfaction with the intervention

    Feasibility outcome 4 will be assessed by a questionnaire developed for the MAP project and will be delivered to all workers (in the MAP teams) and leaders involved in MAP in Roskilde, Lejre, and CAMHS. The intervention will be deemed acceptable if \>70% of MAP team staff and leaders will continue to prioritize the intervention.

    Time frame: Assessment within 2 weeks after the intervention period ends.

  5. Feasibility Outcome 5: Reliability of the measurement of change in youth's social function

    Feasibility outcome 5 will be deemed acceptable if ≥70% of youths who consented to participate in the MAP project, participated in the 'Personal and Social Performance Scale Interviews at baseline and after 1 year.

    Time frame: Assessment within 2 weeks after the intervention period ends.

Other outcomes

  1. Primary exploratory outcome: Change in youths' social function

    Change in youths' social function covering four domains (socially useful activities, personal and social relationships, self-care, disturbing and aggressive behaviors, measured with the Personal and Social Performance (PSP) Scale, rated by researchers using multiple sources of information. Overall functioning will be scored on a scale from 0 (minimum value \[worst outcome\], complete lack of autonomy) to 100 (maximum value \[best outcome\], excellent functioning).

    Time frame: The PSP interview will be conducted at baseline and at end of intervention (after 52 weeks, +/- 14 days).

  2. Monitoring of adverse events

    We anticipate no or minimal adverse effects or adverse events related to the AMBIT and MAU interventions in the trial. The independent observer will be responsible for the recording and classification of events based on the weekly contact with the participants and surveillance of the electronic health record system (Sundhedsplatformen) to cover adverse events according to the following definitions: Adverse Event (AE): any undesirable medical event occurring to a participant during a clinical trial, which does not necessarily have a causal relationship with the intervention. Adverse Reaction (AR): any undesirable and unintended medical response related to the intervention occurring to a participant during a clinical trial. Serious Adverse Event (SAE): any adverse event that results in death, is life-threatening, requires hospitalization or prolongation of existing hospital stay

    Time frame: Weekly screening for adverse events during the complete 52 weeks treatment.

  3. Secondary exploratory outcomes: Participation in education, employment, or training in the past four weeks

    Participation in education, employment, or training in the past four weeks, rated by an independent observer based on multiple sources of information from a short interview in connection with the Personal and Social Performance Scale assessment.

    Time frame: The assessment will be conducted at baseline and at end of treatment (after 1 year, +/- 14 days).

  4. Secondary exploratory outcomes: Change in well-being

    Change in well-being, self-reported with the WHO-5 well-being index. The WHO-5 includes 5 questions scored on a Likert scale from 0 (low well-being) to 5 (high well-being) resulting in a sum score of 0 to 25.

    Time frame: The questionnaire is administered to the young person and the primary parent/caregiver at baseline, midway (after 182 days +/- 14 days), and after 1 year (365 days +/- 30 days) to measure changes before, during, and after the treatment period.

  5. Secondary exploratory outcomes: Change in personal recovery

    Change in personal recovery, self-reported, measured by the Brief INSPIRE-O, which has recently been validated in a Danish context. The Brief INSPIRE-O includes 5 questions scored on a Likert scale from 0 (low well-being) to 4 (high well-being) resulting in a sum score of 0 to 20.

    Time frame: The questionnaire is administered to the young person and the primary parent/caregiver at baseline, midway (after 182 days +/- 14 days), and after 1 year (365 days +/- 30 days) to measure changes before, during, and after the treatment period.

  6. Secondary exploratory outcomes: Change in health-related quality of life

    Change in health-related quality of life measured by the Child Health Utility 9D (CHU9D), self- and parent-reported. All nine items of the CHU9D have five unnumbered response options which are converted to scores of 1-5, resulting in a sum score of 9 to 45. The instrument allows for the calculation of Quality-Adjusted Life Years (QALYs). It is a measure used to assess how many good life years are gained or lost by introducing new health technology or organization.

    Time frame: The questionnaire is administered to the young person and the primary parent/caregiver at baseline, midway (after 182 days +/- 14 days), and after 1 year (365 days +/- 30 days) to measure changes before, during, and after the treatment period.

  7. Secondary exploratory outcomes: Mental health problems and disorders

    Mental health problems and disorders measured by the Strengths and Difficulties Questionnaire (SDQ) (Goodman, 1999), self- and parent-reported. The SDQ contains 25 items, which cover five subscales relating to the children's emotional problems, peer problems, behavioral problems, hyperactivity and pro-social behavior. Responses to the subscales on emotional problems, peer problems, behavioral problems, and hyperactivity can be used to calculate a total difficulties score. Each subscale score ranges from 0-10, implying that the total difficulties score ranges from 0 to 40 An impact score is calculated from five items; whether the difficulties upset or distress the child and how much the difficulties interfere with home life, friendships, classroom learning, and leisure activities. Each item is scored on a scale from 0 to 10. To score 1 or 2, the interference from the difficulties in that domain must be assessed to either "quite a lot" or "a great deal", resulting in an impact score.

    Time frame: The questionnaire is administered to the young person and the primary parent/caregiver at baseline, midway (after 182 days +/- 14 days), and after 1 year (365 days +/- 30 days) to measure changes before, during, and after the treatment period.

  8. Secondary exploratory outcomes: Participant satisfaction

    Participant satisfaction measured with the Client Satisfaction Questionnaire, self-reported. The scale consists of 8 questions scored on a 4-point Likert Scale ranging from low to high satisfaction with different aspects of the intervention. The total score ranges from 8 (minimum value \[bad outcome\], low satisfaction) to 32 (maximum value \[good outcome\], high satisfaction).

    Time frame: The questionnaire is administered to the participant at the end of intervention (after 52 weeks + / - 2 weeks)

  9. Secondary exploratory outcomes: Parental satisfaction

    Parental satisfaction and experience with the treatment of their child will be measured with the Experience of Service Questionnaire. The scale consists of 10 questions scored on a 3-point Likert Scale. The total score ranges from 0 (minimum value \[bad outcome\], poor satisfaction\]) to 20 (maximum value \[good outcome\], high satisfaction\]).

    Time frame: The questionnaire is administered to the primary parent/caregiver at the end of intervention (after 52 weeks + / - 2 weeks)

  10. Secondary exploratory outcomes: Adherence to planned care in CAMHS

    Adherence to planned care in CAMHS and the use of emergency healthcare will be assessed through information from the young person's patient records.

    Time frame: All planned and completed appointments with CAMHS will be documented by the investigators during the complete 52 weeks of intervention. The investigators will screen for emergency healthcare service use weekly during the complete 52 weeks of intervention

07

Study locations

1 of 1 sites recruiting
  • Child and Adolescent Psychiatric Department, Psychiatry Region Zealand
    Roskilde, Region Sjælland 4000, Denmark
    Recruiting
    • Pia Jeppesen, Professor, Ph.d. · Contactpijep@regionsjaelland.dk · 23969929
    • Kristine Hansen, MD · Contactktrh@regsj.dk · +4553639199
    • Martin Køster Rimvall, MD, phD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — The pseudonymous quantitative data can be made available from six months after the publication date of the scientific articles written by the PhD student (from 2029). Proposals for use of data and requests for access should be directed to the principal investigator Pia Jeppesen, mail: pijep@regionsjaelland.dk. To gain access, researchers will need to sign a data access agreement with the Department of Child and Adolescent Psychiatry, Copenhagen University Hospital - Psychiatry Region Zealand, Roskilde, Denmark. The pseudonymous individual participant data can be made available to investigators for research that have been approved by independent review committees. The data access will be granted on a case-by-case basis by the principal investigator. Access will be granted to the extent permissible by the General Data Protection Regulation and the Danish Data Protection Act. Making the data available may require approval from the Danish Data Protection Authority.

Supporting information: Study protocol, Statistical analysis plan

Time frame: The IPD including the SAP will become available 6 months after the publication of the summary of all results of the feasibility trial (expected access in 2029). The study protocol will be published during the period of recruitment of participants in 2025-26.

Access criteria: The IPD and supporting information will be available for researchers upon request for research that have been approved by independent review committees and to the extent permissible by the General Data Protection Regulation and the Danish Data Protection Act. Making the data available may require approval from the Danish Data Protection Authority. The pseudonymous quantitative data will be shared electronically in excel sheets.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Jan 2028, 34 months after the start.

Of 42 non-industry interventional studies with no phase under Social Adjustment, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 45. This study's planned 34 months is above that.

Counting every sponsor, half of 43 studies reached it within 18 months; a quarter within 6 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2025
First posted
Mar 20, 2025
StartActual
Mar 25, 2025
Primary completionEst.
Jan 31, 2028
CompletionEst.
Jan 31, 2028
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06886165
Lead sponsor
Pia Jeppesen
Collaborators
Lejre Municipality, Roskilde Municipality, Child and Adolescent Mental Health Services, Region Zealand, Copenhagen University Hospital, Hvidovre
Responsible party
Pia Jeppesen (Professor, PhD, Head of Research, Department of Child and Adolescent Psychiatry, Psychiatric Research Unit, Region Zealand, Denmark) — Sponsor-investigator
First posted
Mar 20, 2025
Start date
Mar 25, 2025
Primary completion
Jan 31, 2028 (estimated)
Completion
Jan 31, 2028 (estimated)
Last update
Sep 18, 2026

Study contacts

Pia Jeppesen, Professor, MD
Contact
pijep@regionsjaelland.dk
+45 58538002
Kristine T Hansen, MD, ph.D-Student
Contact
ktrh@regionsjaelland.dk
+4558538002
Pia Jeppesen, Professor, MD
principal investigator · University of Copenhagen and head of the Research Department in the Child and Adolescent Mental Health Services, Region Zealand
Martin Køster Rimvall, PhD, MD
principal investigator · Research Department in the Child and Adolescent Mental Health Services, Region Zealand

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion